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Abstract
Background: There is ongoing debate about the harms and benefits of a national prostate cancer screening
programme. Several model-based cost-effectiveness analyses have been developed to determine whether the
benefits of prostate cancer screening outweigh the costs and harms caused by over-detection and over-treatment,
and the different approaches may impact results.
Methods: To identify models of prostate cancer used to assess the cost-effectiveness of prostate cancer screening
strategies, a systematic review of articles published since 2006 was conducted using the NHS Economic Evaluation
Database, Medline, EMBASE and HTA databases. The NICE website, UK National Screening website, reference lists
from relevant studies were also searched and experts contacted. Key model features, inputs, and cost-effectiveness
recommendations were extracted.
Results: Ten studies were included. Four of the studies identified some screening strategies to be potentially
cost-effective at a PSA threshold of 3.0 ng/ml, including single screen at 55 years, annual or two yearly screens
starting at 55 years old, and delayed radical treatment. Prostate cancer screening was modelled using both
individual and cohort level models. Model pathways to reflect cancer progression varied widely, Gleason grade
was not always considered and clinical verification was rarely outlined. Where quality of life was considered, the
methods used did not follow recommended practice and key issues of overdiagnosis and overtreatment were
not addressed by all studies.
Conclusion: The cost-effectiveness of prostate cancer screening is unclear. There was no consensus on the optimal
model type or approach to model prostate cancer progression. Due to limited data availability, individual patient-level
modelling is unlikely to increase the accuracy of cost-effectiveness results compared with cohort-level modelling, but is
more suitable when assessing adaptive screening strategies. Modelling prostate cancer is challenging and the justification
for the data used and the approach to modelling natural disease progression was lacking. Country-specific data are
required and recommended methods used to incorporate quality of life. Influence of data inputs on cost-effectiveness
results need to be comprehensively assessed and the model structure and assumptions verified by clinical experts.
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Background
Prostate cancer is the most common cancer in men in
Europe and the second most common cancer in men
worldwide. In 2012, 417,000 cases were diagnosed in
Europe and 1,111,000 cases worldwide [1], so the disease
has an important impact on healthcare resources. Symp-
tomatic cases usually occur when the disease has metasta-
sised and curative treatments are unlikely to be effective.
A screen test, prostate-specific antigen (PSA) blood test,
followed by a biopsy can be used to detect prostate can-
cers when asymptomatic and localised within the prostate
gland, but PSA is not a specific marker for prostate cancer
and prostate biopsy is associated with adverse effects [2].
Current diagnostic methods lead to over-detection of can-
cers that may not progress to become clinically important
in a man’s lifetime, but can also miss aggressive, poten-
tially fatal prostate cancers [3]. Treatments also have con-
sequences. While the UK ProtecT trial of treatments for
PSA-detected localised prostate cancer observed only 1%
mortality in men with prostate cancer after a median 10-
year follow-up, there were increased risks of disease pro-
gression and metastases following active monitoring [4]
and impacts on urinary, sexual and bowel function from
radical surgery or radiotherapy [5].
Large trials (ERSPC and PLCO) have quantified poten-
tial benefits from various screening strategies, but also
confirmed considerable harms from overdiagnosis and
overtreatment [6–8]. The US Preventive Services Task
Force review, considering the totality of evidence, found
limited prostate cancer-specific mortality benefit insuffi-
cient to outweigh the risks of overtreatment and harms
[9]. However, to account for evidence from recent trials
the recommendation is being revised to indicate a ‘po-
tential’ benefit of reducing cancer-specific mortality.
This potential benefit of screening may be observed in
men whose prostate cancer is destined to progress.
Other men are, on the other hand, subjected to unneces-
sary tests and treatments, which are costly both eco-
nomically on healthcare resources and in harm caused
to patients.
Policy decisions about whether the potential benefits
of screening outweigh the costs and harms require a for-
mal comparison of the costs and consequences of alter-
native courses of action through an economic
evaluation. Many international institutes recommend
cost-utility analysis, measuring health-related outcomes
using quality-adjusted life-years (QALYs) combining
length with quality of life measured by generic instru-
ments (e.g. EQ-5D or SF-6D) to enable comparisons to
be drawn across services [10–16]. As much of the bene-
fit or harm arises from subsequent treatment, the value
of any screening test is best understood by assessing the
care pathway over a patient’s lifetime using decision ana-
lytic modelling [17].
Since the mid-1990s, several model-based cost-
effectiveness analyses have been published for prostate
cancer screening using different methods that may
impact on results. The aim of this study was to system-
atically review model-based cost-effectiveness analyses
to; (1) provide an overview of cost-effectiveness recom-
mendations, (2) identify similarities and deviations in the
evidence base and methods used, and (3) identify key
issues to inform future analyses.
Methods
Search strategy
In April 2016, studies were identified by searching the
NHS Economic Evaluation Database (EED), Medline,
EMBASE, HTA databases, NICE guidelines, UK National
Screening Committee guidance, reference lists from rele-
vant studies and contacting experts. Search terms in-
cluded free text and MESH terms (See Additional file 1
for search strategies).
The search was limited to English language publica-
tions and studies published between January 2006 and
April 2016. An update was performed from April 2016–
February 2017. Reports from NICE and UK National
Screening Committee were considered as they are im-
portant inputs to UK decision-making and can inform
practice in other countries. The review was restricted to
evidence from January 2006 onward to reflect current
practice in screening for prostate cancer and economic
evaluation modelling methods.
The guidelines from the Centre for Reviews and Dis-
semination, PRISMA and Cochrane collaboration for re-
views were followed [18–20].
Inclusion criteria
Included studies reported: i) a model-based economic
evaluation of any PSA screening strategy; or ii) natural
history models of prostate cancer that were used to in-
form the model structure for cost-effectiveness analysis.
Studies evaluating any PSA strategy were considered.
Men of any age and in any country were included. Any
economic evaluation type was included.
Study selection and data extraction
Study selection was performed independently by two
reviewers (SS and SM): the first stage considered the
relevance of the title and abstract, and the second in-
volved reading the full text of potentially relevant papers.
Relevant studies were carried forward for data extrac-
tion. 10% of the title and abstracts and all full text
papers were reviewed by a second reviewer.
As the purpose of the review was to report the meth-
odological approaches used in model-based economic
evaluations, a formal quality checklist was not used to
select studies, but relevant sections of an existing
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economic evaluation checklist along with recommenda-
tions from NICE were used to extract and evaluate stud-
ies [10, 21]. Key clinical issues, such as reporting of
overdiagnosis were included (see Additional file 1 for
data extraction criteria). Due to the nature of the review,
a narrative synthesis of data was undertaken.
Results
In total, 1324 studies were identified. After removing
duplicates and checking for eligibility, 34 full text papers
were retrieved (Fig. 1). Ten studies were included in the
review: nine model-based economic evaluations were
identified and one study identified the number needed
to treat to identify a cost-effectiveness threshold [22].
The latter study was included as the model type, struc-
ture and parameters could potentially answer the review
question.
Study type
The study characteristics are presented in Table 1. Pros-
tate cancer screening strategies were compared in sev-
eral countries, including UK (n = 3), Australia (n = 2), US
(n = 1), Canada (n = 1) and Europe (n = 1) with two stud-
ies not reporting the country setting.
Most of the studies reported a cost-utility analysis,
where outcomes are presented in QALYs gained [23–30].
Three of these studies also reported outcomes in terms of
life years gained or saved [26, 28, 29]. The remaining
studies considered only reporting life years gained or
saved [22, 31], but recommendations are difficult to inter-
pret as a conventional threshold for determining cost-
effectiveness has not been established based on cost per
life-year gained [22, 31].
All included studies assessed the cost-effectiveness of a
screening programme by considering the screen, test
and treatment pathway for men over a lifetime (ranging
from up to 80–100 years old), except one [29], which
modelled up until 70 years old due to data availability.
Screening strategies
All studies estimated the cost-effectiveness of more
than one PSA screening strategy (Table 2). Screening
interventions can be categorised accordingly: (1) Single
Fig. 1 Flow diagram of study selection process
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Table 2 Cost-effectiveness results for studies reporting QALYs
Study Setting Strategies compared PSA threshold ICER (Cost/QALY
gained)
Threshold
Chilcott et al. [23] UK · single screen at 50 3.0 ng/ml Dominateda £20–30,000/QALY gained
· screen every 4 years from 50 to 74 years 3.0 ng/ml Dominated
· screen every 2 years 50–74 years 3.0 ng/ml Dominated
· screen every year from 50 to 74 3.0 ng/ml Dominated
· screen at 50, 60, 65, 70 3.0 ng/ml Dominated
· screen every 4 years 50–70, 55–74, 55–70 3.0 ng/ml Dominated
· screen every 2 years 50–70, 55–74, 55–70 3.0 ng/ml Dominated
Heijnsdijk et al. [25]
Costs in US dollars
NR 68 scenarios (efficient strategies only): 3.0 ng/ml No formal threshold
· single screen at 55 years 3.0 ng/ml $31,467
· screen at 55 and then 57 years 3.0 ng/ml $38,563
· screen at 55 and then 58 years 3.0 ng/ml $40,785
· screen every 2 years 55–59 years 3.0 ng/ml $45,615
· screen every 2 years 55–61 years 3.0 ng/ml $54,349
· screen yearly 55–61 years 3.0 ng/ml $63,263
· screen yearly 55–62 years 3.0 ng/ml $69,481
· screen yearly 55–63 years 3.0 ng/ml $76,910
Hummel and Chilcott
[24]
UK · single screen at 50 3.0 ng/ml Dominated £20–30,000/QALY gained
· screen every 4 years from 50 to 74 years 3.0 ng/ml Dominated
· screen every 2 years 50–74 years 3.0 ng/ml Dominated
· screen every year from 50 to 74 years 3.0 ng/ml Dominated
Keller et al. [29] Australia · opportunistic screening (current practice) 3.0 ng/ml to 2.5 ng/ml A$50,000/QALY gained
· screen every 2 years from 50 to 69 years
(immediate treatment)
3.0 ng/ml to 2.5 ng/ml A$147,528
· screen every 2 years from 50 to 69 years
(AS for low risk cancer)
A$45,882
Kobayashi et al. [27]
Costs in US dollars
NR · annual screen irrespective of baseline, 50–70 N/A $165,938 No formal threshold
· baseline PSA≤ 1.0 ng/ml biennial
rescreening, 50–70
1.0 ng/ml $46,505
· baseline PSA≤ 2.0 ng/ml biennial
rescreening, 50–70
2.0 ng/ml $5925
· baseline PSA≤ 3.0 ng/ml biennial
rescreening, 50–70
3.0 ng/ml
· baseline PSA≤ 4.0 ng/ml biennial
rescreening. 50–70
4.0 ng/ml Dominated
Martin et al. [30] Australia · average risk screen: every 4 years, 50+ 4.0 ng/ml A$291,817 A$50,000/QALY gained
· high risk screen: every 4 years, 50+ 4.0 ng/ml A$110,726
· very high risk screen: every 4 years, 50+ 4.0 ng/ml A$30,572
Pataky et al. [26] Canada 14 scenarios: CAN $50–80,000/QALY
gained
· screen at 50, 60, 70 3.0 ng/ml Dominated
· screen at 60 followed by screen at 65 3.0 ng/ml Dominated
· screen every 4 years 55–69, 50–74 3.0 ng/ml Dominated
· screen every 4 years 50–74 3.0 ng/ml, (4.0 ng/ml
for ≥70 years old)
Dominated
· screen every 2 years 60–74, 50–69, 55–74,
50–74, 40–74
3.0 ng/ml Dominated
· screen every 2 years 50–74 3.0 ng/ml, (4.0 ng/ml
for ≥70 years old)
Dominated
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screen (n = 5), (2) Repeat screens (n = 10), and (3)
Adaptive screens (n = 3).
(1)A single screen was assessed in all three UK
studies at ages 50 [23, 24, 31], 55 [31], 60 [31],
and 65 [31] years old. The Canadian study also
assessed a single screen at ages 50, 60, and
70 years old [26], and Heijnsdijk et al. [25]
assessed screening at ages 55–75 years old. All
strategies used a PSA threshold of 3.0 ng/ml.
Overdiagnosis rates, expressed as the percentage
of prostate cancer diagnoses relative to prostate
cancer deaths, for a single screen ranged from
0.06% (50 years), 1.9% (60 years), and 7.1%
Table 2 Cost-effectiveness results for studies reporting QALYs (Continued)
Study Setting Strategies compared PSA threshold ICER (Cost/QALY
gained)
Threshold
· adaptive screen 50–74 3.0 ng/ml Dominated
Roth et al. [28] US 18 scenarios: Contemporary treatment
scenario
· screen yearly 45–69, 50–74, 55–69 4.0 ng/ml Dominated US$ 50,000-150,000/QALY
gained typically referred
to (study refers to
$150,000/QALY gained)
· screen yearly 45–69 10.0 ng/ml US $326,292
· screen yearly 50–74 10.0 ng/ml US $330,065
· screen yearly 55–69 10.0 ng/ml US $300,884
· screen yearly if >3.0 ng/ml, every 2 years
otherwise,45–69
3.0 ng/ml Dominated
· screen yearly if >3.0 ng/ml, every 2 years
otherwise,45–69
10.0 ng/ml US $184,074
· screen every 4 years 50–74 4.0 ng/ml Dominated
· screen every 4 years 50–74 10.0 ng/ml US $170,195
· screen every 4 years 55–69 10.0 ng/ml US$92,446
· screen every 2 years if >1.0 ng/ml, every
4 years otherwise, 50–74
4.0 ng/ml Dominated
· screen every 2 years if >1.0 ng/ml, every
4 years otherwise, 50–74
10.0 ng/ml US $209,338
· screen yearly with age dependent threshold,
50–74
3.5(50–59), 4.5(60–69),
6.5(70–74)
Dominated
· screen yearly with age dependent threshold
50–74
4.5(50–59), 5.5(60–69),
8.5(70–74)
Dominated
· screen every 2 years 55–69 3.0 ng/ml Dominated
· screen every 4 years 55–69 3.0 ng/ml Dominated
· screen every 2 years 55–69 10.0 ng/ml US $170,981
Selective treatment scenarios
· screen yearly 45–69 4.0 ng/ml US $163,214
· screen yearly 50–74 4.0 ng/ml US $243,768
· screen yearly 55–69 4.0 ng/ml US $128,680
· screen yearly if >3.0 ng/ml, every 2 years
otherwise,45–69
3.0 ng/ml US $313,214
· screen every 4 years 50–74 4.0 ng/ml US $89,333
· screen every 2 years if >1.0 ng/ml, every
4 years otherwise, 50–74
4.0 ng/ml US $136,332
· screen yearly with age dependent threshold,
50–74
3.5(50–59), 4.5(60–69),
6.5(70–74)
US $166,784
· screen yearly with age dependent threshold
50–74
4.5(50–59), 5.5(60–69),
8.5(70–74)
US $124,564
· screen every 2 years 55–69 3.0 ng/ml US $120,952
· screen every 4 years 55–69 3.0 ng/ml US $70,831
Italicised text indicates potentially cost-effective scenario. a Dominated; the strategy is more costly and less effective than the comparator (commonly, usual practice)
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(70 years) [26]. Rates of 18% (50 years) were also
reported, expressed as the proportion of men who
died from other causes [23], and 29.7% (55 years)
[25], expressed as the proportional change in
cancer detected between the screen and no screen
arms.
When accounting for quality of life, a single screen
was not shown to be cost-effective in three studies
[23, 24, 26], but one study found that a single screen
at 55 years old may be potentially cost-effective.
($31,470/ QALY gained) [25].
(2)All studies considered repeat screens, including
annual (n = 5), two (n = 6), four (n = 7), and five
(n = 1) yearly intervals in a range of age cohorts
from 40 to 75 years old (see Table 1 for all
strategies). The starting age varied from 40 to
60 years old and the stopping age varied from 55
to 75 years old. Martin et al. [30] was the only
study to compare 4 yearly screening results by
risk and to assess only a PSA threshold of 4.0 ng/
ml. The most common PSA threshold used was
3.0 ng/ml (n = 7), with one study comparing
different thresholds for all men (3.0 ng/ml,
4.0 ng/ml, 10 ng/ml) [28].
Overdiagnosis for repeat screens ranged from 8.4–
21.9% [26], over 44% [23] and between 31.1%–36.7%
[25].
When accounting for quality of life, repeat screening
was not shown to be cost-effective in four studies
[23, 24, 26, 29]. However, two studies found some
strategies to be potentially cost-effective: Screening
every 4 years at ages 55–69 years old at a PSA
threshold of 10 ng/ml ($92,450) [28], screening very
high-risk men every 4 years at a PSA threshold of
4.0 ng/ml (AUS$30,570) [30], and yearly or two-
yearly screens starting at 55 years old and stopping
at ages ranging between 59 and 63 years old (see
Table 2 for details) with incremental cost-
effectiveness ratios (ICERs) ranging from
$38,560–$76,910/QALY gained [25].
(3)Three studies [26–28] assessed the cost-
effectiveness of adaptive screen frequencies, where
the subsequent screen interval was based on the
baseline PSA level [26, 27] or the PSA threshold
for biopsy was dependent on age [26, 28]. None
of the strategies compared were shown to be
cost-effective.
Pataky et al. [26] reported overdiagnosis rates of
5.1% for a strategy where all men are tested at
60 years old, with men above the median screened
again at 65 years old, and 21% for a strategy where
men with a PSA above the age median are screened
again in 2 years and others screened again in
4 years.
Most studies compared screening strategies to ‘no
screen’ despite the relatively high prevalence in practice
of background or opportunistic screening.
Treatment types
All studies referred to a biopsy to confirm diagnosis,
but only four studies detailed the type of biopsy -
TRUS guided [22, 27, 29, 31]. Radical treatments,
such as radiotherapy and prostatectomy with and
without hormone therapy were considered, as well
as conservative treatment. Four different terms were
used to describe the strategy of delayed radical
treatment, and few studies provided details on what
it involved (Additional file 2). Five studies, three of
which found strategies to be cost-effective, explicitly
stated that men on conservative management even-
tually received radical treatment, but the approaches
varied widely [23–25], with different percentages as-
sumed, e.g. 30% of men receive treatment after
7 years in Heijnsdijk et al. [25] and 10% within
2 years in two studies [23, 24]. Whilst the other two
studies, which found strategies to be cost-effective,
based likelihood of progression to radical treatment
on time spent in the disease state [29] or would-be
clinical diagnosis in the absence of a screening
programme [28].
In addition to comparing radical or conservative treat-
ment following diagnosis, two studies also assessed cost-
effectiveness of screening by risk-stratifying treatment
[28, 29]. For example, men with low risk cancer receive
conservative treatment until signs of progression, instead
of immediate radical treatment. Keller et al. [29] found
screening men aged 50–69 years old every 2 years and
managing low risk men with active surveillance to be
cost-effective ($45,882/QALY gained) and Roth et al.
[28] reported a range of screening scenarios to be more
cost-effective when selective treatment practices are
employed when compared to opportunistic screening
and no screening respectively (Table 2).
Keller et al. [29] did not report overdiagnosis, but
noted that an active surveillance treatment strategy for
low risk cancer could limit overtreatment.
Model features
Model type
Cost-effectiveness models involved either a cohort-
level (i.e. macrosimulation) or individual patient-level
(i.e. microsimulation) modelling approach to estimate
the expected costs and outcomes of screening.
Four Markov cohort models were identified [27, 29–31],
where men with similar characteristics are grouped
together and modelled as a cohort. Also, four individual
patient level models [23, 25, 26, 28], where men are simu-
lated individually to allow for variability across individuals
Sanghera et al. BMC Cancer  (2018) 18:84 Page 9 of 15
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were identified. Additionally, one ‘population based
model’ [22], and one natural history model that was con-
verted from a patient-level to a cohort model were also
identified [24].
The model type did not depend on the screening
strategy assessed, except the two studies that
considered adaptive screening strategies were imple-
mented using individual patient-level models, as these
models more readily allow tracking of individual pa-
tients to, for example, recall only moderate to high
risk men for a subsequent screen. Three of the four
microsimulation models were epidemiological natural
Table 4 Characteristics of quality of life values used
Study Study setting Perspective Assessment of QoL Population Country
Chilcott et al. [23] UK NHS HUI/EQ-5D General population UK/other
Heijnsdijk et al. [25] NR Healthcare based on
included costs
SG/EQ-5D/TTO/VAS Patients/experts/ general
population
Netherlands, US,
Canada
Hummel and Chilcott [24] UK NHS HUI/EQ-5D General population UK/other
Keller et al. [29] Australia Healthcare SF-12/ SF-36/
othera, b
General population Australia/ Finland
Kobayashi et al. [27] NR Societal TTO Physicians/ patients Unclear
Martin et al. [30] Australia Healthcare SF-12/ SG Patient/ General population US (adjusted)/
Australia
Pataky et al. [26] Canada Healthcare based on
included costs
SG 2 different patient groups Canada
Roth et al. [28] US US payer perspective SG Patient US
HUI Health utility index, QoL quality of life, SG standard gamble, TTO Time trade off. aThe exact source of the value for advanced disease is unclear, it is likely to
reflect a synthesis of EQ-5D and 15D.b assumed SF measures converted to SF-6D
Table 5 Quality of life values assigned to health states
Study Starting state Diagnosis Treatment Other Advanced End
of life
Adverse effects
Biopsy Cancer Short- term Long-term
Chilcott,
Hummel
[23]
Baseline = age
dependent
– – 0.635 Bowel function = 0.89
Urinary function = 0.94
Sexual dysfunction =0.9
Heijnsdijk
et al. [25]
Screening =
0.99
0.9 0.8 Radiation
= 0.73
Radiation
= 0.78
Post-recovery
= 0.95
0.6 0.4 Short-term & long-term
effect
Prostatectomy
= 0.67
Prostatectomy
= 0.77
Active surveillance
= 0.97
Active surveillance
= 0.97
Hummel
and Chilcott
[24]
Baseline = age
dependent
0.635 Bowel function = 0.89
Urinary function = 0.94
Sexual dysfunction =0.9
Keller et al.
[29]
age dependent/
screening = 1.0
0.95b 0.95b 0.9 to
>0.6b
See treatment: Persistent
effects, 3 years post-
diagnosis
Kobayashi
et al. [27]
Curable = 0.9
Recurrent
= 0.7
0.5 See curable: impotence
& incontinence
Martin et al.
[30]
0.95a 0.5 See cancer
Pataky et al.
[26]
Healthy
screening
population = 1.0
0.88 0.9 Symptomatic
=0.9
0.85 0.5 Short-term & long-term
effect
Roth et al.
[28]
Healthy
screening
population = 1.0
0.75 0.92 Symptomatic
=0.89
0.75 0.33 Short-term & long-term
effect
Surveillance
= 0.92
Surveillance
= 0.92
a Diagnosed and treated. bmultipliers of age dependent baseline value
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history models adapted to assess cost-effectiveness:
The Microsimulation Screening Analysis (MISCAN)
model [25] and the Fred Hutchinson Cancer Research
Centre (FHCRC) model [26, 28]. These models esti-
mate unobservable processes, such as the natural his-
tory of the disease, and are developed to evaluate the
effectiveness of screening programmes or to provide
simulated estimates of overdiagnosis.
Model pathways of prostate cancer
The structure of the model reflects the natural history of
the condition and the impact of screening on disease
progression. The natural history of prostate cancer, par-
ticularly progression from asymptomatic to clinically
detectable disease, is not well understood and has been
captured with differing degrees of detail across the
models due to a lack of data (Table 3).
All but one cohort level model followed the estab-
lished TNM classification, but only one of these four
studies incorporated the likelihood of disease progres-
sion through Gleason grade. Martin et al. [30] reported
4 yearly screening for high risk men to be cost-effective,
but the model pathway did not consider stages or grades
of cancer, only presence or absence of cancer. The
cohort model by Keller et al. [29], which found screening
followed by selective treatment to be cost-effective, was
the only study to model prostate cancer according to the
D’amico classification of low risk (G ≤ 6, PSA ≤ 10,≤T1a),
intermediate (G ≤ 7, PSA ≤ 20, ≤T2b), high (G > 7,PSA >
20,>T2b), and advanced cancer.
All individual patient-level models followed the TNM
classification and incorporated Gleason grade. Similar to
two of the cohort models, two patient-level models com-
bined stages of prostate cancer to represent localised
(T1-T2), locally advanced (T3–4) and metastatic cancer
[23, 24, 27, 31] and each subdivided Gleason grade into
three categories (G < 7, G = 7 and G > 7). Another indi-
vidual level model, which found single screens and
repeat screens to be cost-effective, differentiated the
TNM staging classification by allowing up to 18 stages
(9 pre-clinical and 9 clinical states), where each tumour
stage (T1, 2, 3,4) was modelled individually [25], but the
rationale for such delineation was not provided. This
was also the only study to allow for disease progression
by Gleason grade within a stage [25]; however, the evi-
dence or reasoning for this approach is unclear.
Two further individual-level models refer to loco-
regional (partitioned by ≤T2a vs > T2) and distant dis-
ease states [26, 28]. The natural history model used to
inform these cost-effectiveness models by Pataky et al.
[26] and Roth et al. [28] link cancer progression to PSA
levels and allow post-onset PSA values to differ depend-
ing on Gleason score (8–10 or 2–7). One of these indi-
vidual models found repeat screening every 4 years and
selective treatment following screening to be potentially
cost-effective.
Assessing uncertainty in cost-effectiveness results
All studies conducted a deterministic sensitivity analysis
(where one model input is changed and the others
remain the same) to assess the robustness of the cost-
effectiveness results to changes to model inputs [22–31].
Best case and worst case scenario analyses were con-
ducted where: for example, the highest and lowest qual-
ity of life values were used for the health states [25, 26].
In their sensitivity analyses, all studies that showed a
screening strategy to be potentially cost-effective found
that the results were sensitive to the quality of life values
used [25, 28–30].
Only two of the four cohort-level models and two in-
dividual patient-level simulation models conducted a
more comprehensive assessment of uncertainty, a prob-
abilistic sensitivity analysis [23, 28, 29, 31]. In a probabil-
istic sensitivity analysis, model inputs (e.g. likelihood of
disease progression, screen detection, cost and quality of
life values) are changed simultaneously according to an
appropriate distribution of plausible values. Both Roth et
al. [28] and Keller et al. [29], who found strategies to be
cost-effective conducted a probabilistic sensitivity ana-
lysis, which showed that the strategies had a probability
of approximately 50% or less of being cost-effective at
decision-maker willingness to pay thresholds of $50,000/
QALY gained (US dollars and AUS dollars respectively).
Roth et al. [28], also showed that the probability of cost-
effective increases marginally if the decision-maker
threshold is raised to $150,000/ QALY gained.
Model inputs
Quality of life
The estimated impact on health-related quality of life for
the same health state (e.g. advanced cancer) varied
across the studies (Tables 4 and 5). Two of the ten stud-
ies did not incorporate quality of life [22, 31].
Evidence on quality of life impact was taken only from
secondary sources. The methods used varied across the
studies. Only three studies exclusively used quality of life
values from the same country context [26, 28, 30]; the
remaining studies combined values from different coun-
tries and settings. None of the studies followed recom-
mended methods to estimate quality of life: values that
are derived using the same method in the same popula-
tion group across all the model health states [10], and
quality of life scores that are based on values derived by
the general population [10–16].
Of the four studies that found screening to be cost-
effective, three used some quality of life values that were
based on recommended measures, EQ-5D [25] and SF-
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6D [29, 30]. However, scores from different measures
were combined and two studies respectively used differ-
ent country contexts [25, 29] values or used both patient
and general population values [25, 30]. Although recom-
mended measures were not used and values were not
based on the general population, Roth et al. [28] was the
only study to use the same method across all health
states and values from the same population in the same
country.
Adverse effects
Both Chilcott et al. [23] and Pataky et al. [26] highlighted
that overdiagnosis and overtreatment are captured by qual-
ity of life, through adverse effects [23] and the additional
men overtreated and treated earlier [23, 26]. Although nei-
ther Wolstenholme et al. [31] or Shteynshlyuger &
Andriole [22] captured quality of life, they discussed that
any benefits of life years gained reported were likely to be
outweighed or overestimated due to the quality of life
impacts related to adverse treatment effects.
All cost-utility analyses applied quality of life values
that relate directly or indirectly to adverse effects. The
primary adverse effects were considered: urinary, sexual
and bowel problems following treatment. Two studies
explicitly applied a quality of life decrement for these
adverse effects [23, 24], whilst the remaining studies
applied quality of life values for a post-treatment effect,
which includes patients who did and did not experience
adverse effects.
Three studies, two of which showed strategies to be
cost-effective, used different quality of life values for
‘short-term’ and ‘long-term’ treatment effects, which im-
plicitly allows for the adverse effects associated with
treatment [25, 26, 28]. Though there appears to be no
consensus on the length of time that constitutes a short
or long-term effect. Two studies, one which showed
strategies to be cost-effective, referred to short-term
treatment as the first 2 months post-treatment [25, 26]
and the third study, which showed strategies to be cost-
effective, referred to short term as up to one-year post-
treatment [28]. Of the remaining two studies that
showed strategies to be potentially cost-effective, Martin
et al. [30], applied a quality of life score to ‘prostate can-
cer’ (diagnosis and treatment), which was a decrement
averaged over the survival period, obtained from patients
who experienced urinary, bowel and sexual problems,
and Keller et al. [29] considered only persistent adverse
effects 3 years post-diagnosis.
Resource use
Seven studies (including three of the four studies which
showed strategies to be cost-effective) took a healthcare
perspective for the analysis [23–26, 29–31], including
the cost of procedures, equipment and resource use
(staff time) associated with the screening test, biopsy,
treatments, GP visits, hospital admissions and proce-
dures, as well as terminal care costs. Two studies took a
societal perspective, which includes direct healthcare
costs as well costs to patients, carers, and other sectors
(such as lost productivity), but costs were not explicitly
reported [22, 27], making it difficult to assess the appro-
priateness of the included costs. The final US study,
which showed strategies to be cost-effective, took a US
payer perspective [28], where healthcare perspective
costs were included, but the inclusion of out of pocket
costs to patients was unclear. Costs associated with treat-
ment complications were explicitly excluded in two stud-
ies [23, 24], explicitly included in two studies (one of
which showed strategies to be cost-effective) [28, 31], with
the Keller et al. study including only immediate complica-
tions [29], it is unclear whether they were included in the
remaining studies.
Discussion
Several model-based economic evaluations assessing
many different PSA screening strategies were identified.
Strategies ranging from different PSA thresholds, screen-
ing intervals, and age cohorts of men were assessed.
Four of the ten studies identified screening strategies
that could be potentially cost-effective including; delayed
radical treatment for low risk cancer, single screen at
55 years old (3.0 ng/ml), annual or two-yearly screens at
55 years old (3.0 ng/ml) with stopping ages between 59
and 63 years old, screening very high-risk men every
4 years (4.0 ng/ml), and screening men aged 55–69 years
old every 4 years (10 ng/ml). However, these studies
found the results to be sensitive to the quality of life
values used and revealed a lack of good quality data for
the country context to inform the cost-effectiveness
analysis.
Similarities, deviations and key issues for future models
Most studies considered TNM and approximately half
considered Gleason grade to model prostate cancer pro-
gression, but the degree to which TNM and Gleason
grade was incorporated varied across the studies. This
may reflect the lack of agreement or changing trends
overtime on how best to represent prostate cancer pro-
gression. Extensive clinical input and exploration of
alternative model structures in sensitivity analyses to cat-
egorise prostate cancer could alleviate these issues, but
both disease stage and grade should be incorporated, as
these characteristics inform treatment decisions [32].
There was no consensus on the optimal model type
for modelling prostate cancer screening. Adaptive
screening, where subsequent screens are based on risk
stratification, was modelled using individual-patient level
models. This model-type readily accounts for the
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complexity of the disease natural history and the re-
quirements to model adaptive screening strategies, but
additional data and model assumptions are required to
populate these models. The increased flexibility in ana-
lysis should not result in more trust being placed in the
model than is warranted, where limited country-specific
empirical evidence is available, as these individual-level
models are unlikely to increase the accuracy of cost-
effectiveness results. When adaptive screening is not
considered, cohort-level modelling may be more suitable
to evaluate the cost-effectiveness of prostate cancer
screening. Further, when making recommendations to
decision-makers, it is crucial to estimate uncertainty
associated with the model inputs used, regardless of
model type used. Fewer than half the studies conducted
the more comprehensive assessment of uncertainty to
assess the robustness of the cost-effectiveness result to
changes in model inputs.
Most studies incorporated quality of life to account for
the impact on morbidity of screening and treatment,
which is recognised as an appropriate method for cap-
turing the impact of overdiagnosis and overtreatment.
However, recommended methods for capturing quality
of life were rarely followed and the combination of dif-
ferent values derived from different measures from
different populations impacts on the meaningfulness of
the results, as the measures and values from different
populations are not comparable.
Several studies, three of which showed strategies to be
cost-effective, may be at risk of overestimating the bene-
fit of screening by not considering opportunistic or
background screening, which varies considerably across
countries. To ensure that the cost-effectiveness results
are appropriately estimated, the comparator of no sys-
tematic screen should include opportunistic screening.
Finally, given the high rates of overdiagnosis and over-
treatment in prostate cancer, the cost and quality of life
associated with screening, treatments and adverse events
should be incorporated in a cost-effectiveness analysis to
capture the impact of overdiagnosis and overtreatment.
Strengths and limitations
This systematic review provides updated evidence on
the modelling methods used to date to assess the
cost-effectiveness of prostate cancer screening. Three
reviews in the area were identified [23, 33, 34], but
two did not address the specific review question
posed here (see Additional file 1) and the other is
now 8 years old. A limitation of the current review is
that a comparison between the modelling outputs was
not possible because no two modelling methods,
treatment options, or outcome measures were the
same or assessed in the same country context.
Conclusion
The answer to the question of whether screening for
prostate cancer is cost-effective is unclear. Despite sev-
eral model-based evaluations, robust evidence to inform
cost-effectiveness is lacking. Current country-specific
data are required, along with prospective quality of life
data that are incorporated into clinically verified models
using recommended methods. Any recommendations to
decision-makers should be comprehensively tested for
uncertainty in model inputs.
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